United Kingdom

Cytospire Therapeutics secures £61M Series A to advance Next-Generation Cancer Immunotherapies
London-based Cytospire Therapeutics has raised £61 million in Series A funding to accelerate development of its novel immune cell engager therapies for cancer treatment.

The best Articles in our Network